Table 3.

Secondary Efficacy End Points: Mean change in Lanza score, Heartburn score and number of erosions.

Visit	Test (N = 154)	Comparator (N = 76)	P – valueb
Lanza Score
Visit 1 (Baseline)	0.610 ± 0.8805	0.618 ± 0.8789	0.9481
Visit 5 (Week 12)	0.577 ± 0.8713	0.750 ± 0.9457	0.1804
Change from baseline to week 12	−0.054 ± 0.7424	0.153 ± 0.7811	0.0581
Visit 7 (Week 24)	0.403 ± 0.7455	0.526 ± 0.8714	0.2646
Change from baseline to week 24	−0.208 ± 0.7977a	−0.092 ± 0.9685	0.3691
Heartburn score
Visit 1 (Baseline)	0.325 ± 0.5098	0.447 ± 0.5265	0.0908
Visit 5 (Week 12)	0.235 ± 0.4554	0.303 ± 0.4624	0.2957
Change from baseline to week 12	−0.059 ± 0.5409	−0.053 ± 0.5137	0.9340
Visit 7 (Week 24)	0.176 ± 0.3825	0.250 ± 0.4655	0.2646
Change from baseline to week 24	−0.111 ± 0.5201a	−0.105 ± 0.6018	0.1315
Number of erosions
Visit 1 (Baseline)	1.396 ± 2.4877	1.145 ± 2.0113	0.4119
Visit 5 (Week 12)	1.228 ± 2.9158	1.528 ± 2.6695	0.4629
Change from baseline to week 12	−0.215 ± 2.6523	0.528 ± 2.4551	0.0470
Visit 7 (Week 24)	0.968 ± 2.5754	1.474 ± 3.6276	0.2787
Change from baseline to week 24	−0.429 ± 2.0859a	0.329 ± 3.2224	0.0648

Test: Fixed dose combination of Aspirin 150 mg and Pantoprazole 20 mg.

Comparator: Aspirin 150 mg.

Data expressed as mean ± SD.

^aP < 0.05 (based on Paired T test; as compared to baseline).

^bP values based on Un-paired T test.